Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

603
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
603
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

741
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
741
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

566
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
566
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

695
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
695
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

706
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
706
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

405
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
405

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients.

The American journal of cardiology·2026
Same author

Diagnostic Performance and Interpreter Experience of 1-Hour Versus 3-Hour <sup>99m</sup>Tc-HMDP Cardiac Amyloid Radionuclide Imaging: A Prospective, Blinded Comparison.

Circulation. Cardiovascular imaging·2025
Same author

Comparative performance of <sup>99m</sup>Tc-pyrophosphate vs. <sup>99m</sup>Tc-hydroxymethylene diphosphonate for cardiac amyloid radionuclide imaging.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2025
Same author

Refining Carotid Stenting Through Mesh-Integrated Stent Design.

JACC. Cardiovascular interventions·2025
Same author

Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial.

European heart journal·2025
Same author

Delayed-Onset ICI-Associated Myocarditis: When Immunotherapy's Cardiac Consequences Outlast Treatment.

JACC. Case reports·2025

関連する実験動画

Updated: Mar 11, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

ハイパルトロフィック閉塞性心筋病

Josef Veselka1, Nandan S Anavekar2, Philippe Charron3

  • 1Department of Cardiology, 2nd Medical School, Charles University and Motol University Hospital, Prague, Czech Republic.

Lancet (London, England)
|December 4, 2016
PubMed
まとめ

ハイパルトロフィック阻害性心筋病 (HOCM) は,心臓の壁が厚くなり,出血が阻害される遺伝性心筋疾患である. 診断には臨床評価と画像検査が含まれており,重症の場合,除細動器や隔膜縮小療法などの治療が行われます.

さらに関連する動画

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

18.0K

関連する実験動画

Last Updated: Mar 11, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

18.0K

科学分野:

  • 心臓病科
  • 遺伝学
  • 内科 医学

背景:

  • ハイパルトロフィック閉塞性心筋病 (HOCM) は,主として遺伝する心筋疾患である.
  • 異常な負荷状態とは無関係な心臓の膨張 (壁の厚さ ≥15mm) が特徴です.
  • 左心室の流出管阻害 (LVOTO) は,≥30mmHgとして定義される重要な特徴です.

研究 の 目的:

  • ハイパルトロフィック閉塞性心筋病の主要な特徴を定義する.
  • HOCMの診断方法を概説する.
  • HOCMの現在の管理戦略とその合併症を要約する.

主な方法:

  • 診断は通常,臨床表現に基づいて疑われます.
  • 画像処理方法は,重度の確認と評価に不可欠です.
  • 心臓発作による突然死やその他の合併症の リスクの分類は不可欠です

主要な成果:

  • 一般的な症状には呼吸不全,胸痛,心拍,昏睡などがあります.
  • 患者は突然の心臓死,心不全,心房細動のリスクが高くなります.
  • 特定されたリスクと症状に対する効果的な管理戦略が存在します.

結論:

  • HOCMは迅速な診断とリスク評価を必要とする.
  • 治療には,突然の心臓死のリスクに対するカーディオバーター-デフィブリレーターインプラントなどの標的治療が含まれます.
  • 重度のLVOTO症状では,セプト縮小療法 (筋切除またはアルコールのセプト切除) が推奨されます.
  • 終身の抗凝固薬は,心房細動のエピソード後に示されています.